{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T12:36:53Z","timestamp":1791463013756,"version":"4.3.4"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2017,6,15]],"date-time":"2017-06-15T00:00:00Z","timestamp":1497484800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Astellas Pharma Inc"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urogynecol J"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1007\/s00192-017-3377-5","type":"journal-article","created":{"date-parts":[[2017,6,15]],"date-time":"2017-06-15T09:44:17Z","timestamp":1497519857000},"page":"273-283","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["A prospective, double-blind, randomized, two-period crossover, multicenter study to evaluate tolerability and patient preference between mirabegron and tolterodine in patients with overactive bladder (PREFER study)"],"prefix":"10.1007","volume":"29","author":[{"given":"David","family":"Staskin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sender","family":"Herschorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Fialkov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Le Mai","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry","family":"Walsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol R.","family":"Schermer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,6,15]]},"reference":[{"issue":"1","key":"3377_CR1","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s00192-009-0976-9","volume":"21","author":"BT Haylen","year":"2010","unstructured":"Haylen BT, de Ridder D, Freeman RM, Swift SE, Berghmans B, Lee J, et al. An International Urogynecological association (IUGA)\/International continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Int Urogynecol J. 2010;21(1):5\u201326.","journal-title":"Int Urogynecol J"},{"issue":"5","key":"3377_CR2","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1002\/nau.22609","volume":"33","author":"MJ Drake","year":"2014","unstructured":"Drake MJ. Do we need a new definition of the overactive bladder syndrome? ICI-RS 2013. Neurourol Urodyn. 2014;33(5):622\u20134.","journal-title":"Neurourol Urodyn"},{"issue":"11","key":"3377_CR3","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1111\/j.1464-410X.2008.07601.x","volume":"101","author":"KS Coyne","year":"2008","unstructured":"Coyne KS, Sexton CC, Irwin DE, Kopp ZS, Kelleher CJ, Milsom I. The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study. BJU Int. 2008;101(11):1388\u201395.","journal-title":"BJU Int"},{"issue":"4","key":"3377_CR4","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/j.eururo.2013.11.010","volume":"65","author":"K Maman","year":"2014","unstructured":"Maman K, Aballea S, Nazir J, Desroziers K, Neine ME, Siddiqui E, et al. Comparative efficacy and safety of medical treatments for the management of overactive bladder: a systematic literature review and mixed treatment comparison. Eur Urol. 2014;65(4):755\u201365.","journal-title":"Eur Urol"},{"issue":"2","key":"3377_CR5","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.eururo.2012.10.016","volume":"63","author":"V Khullar","year":"2013","unstructured":"Khullar V, Amarenco G, Angulo JC, Cambronero J, Hoye K, Milsom I, et al. Efficacy and tolerability of mirabegron, a beta(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial. Eur Urol. 2013;63(2):283\u201395.","journal-title":"Eur Urol"},{"issue":"10","key":"3377_CR6","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1007\/s00192-012-1724-0","volume":"23","author":"AA Bhide","year":"2012","unstructured":"Bhide AA, Digesu GA, Fernando R, Khullar V. Use of mirabegron in treating overactive bladder. Int Urogynecol J. 2012;23(10):1345\u20138.","journal-title":"Int Urogynecol J"},{"issue":"3","key":"3377_CR7","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.eururo.2008.06.047","volume":"54","author":"CR Chapple","year":"2008","unstructured":"Chapple CR, Khullar V, Gabriel Z, Muston D, Bitoun CE, Weinstein D. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol. 2008;54(3):543\u201362.","journal-title":"Eur Urol"},{"issue":"7","key":"3377_CR8","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1111\/j.1464-410X.2008.07769.x","volume":"102","author":"RK Basra","year":"2008","unstructured":"Basra RK, Wagg A, Chapple C, Cardozo L, Castro-Diaz D, Pons ME, et al. A review of adherence to drug therapy in patients with overactive bladder. BJU Int. 2008;102(7):774\u20139.","journal-title":"BJU Int"},{"issue":"2 Suppl","key":"3377_CR9","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.urology.2006.05.044","volume":"68","author":"P Abrams","year":"2006","unstructured":"Abrams P, Artibani W, Gajewski JB, Hussain I. Assessment of treatment outcomes in patients with overactive bladder: importance of objective and subjective measures. Urology. 2006;68(2 Suppl):17\u201328.","journal-title":"Urology"},{"issue":"6","key":"3377_CR10","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1046\/j.1464-410x.1999.00004.x","volume":"83","author":"G Kobelt","year":"1999","unstructured":"Kobelt G, Kirchberger I, Malone-Lee J. Review. Quality-of-life aspects of the overactive bladder and the effect of treatment with tolterodine. BJU Int. 1999;83(6):583\u201390.","journal-title":"BJU Int"},{"issue":"4","key":"3377_CR11","first-page":"579","volume":"3","author":"M Weaver","year":"1997","unstructured":"Weaver M, Patrick DL, Markson LE, Martin D, Frederic I, Berger M. Issues in the measurement of satisfaction with treatment. Am J Manag Care. 1997;3(4):579\u201394.","journal-title":"Am J Manag Care"},{"issue":"3","key":"3377_CR12","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1002\/nau.20455","volume":"27","author":"E Piault","year":"2008","unstructured":"Piault E, Evans CJ, Espindle D, Kopp Z, Brubaker L, Abrams P. Development and validation of the overactive bladder satisfaction (OAB-S) questionnaire. Neurourol Urodyn. 2008;27(3):179\u201390.","journal-title":"Neurourol Urodyn"},{"key":"3377_CR13","unstructured":"Piault E, Evans CJ, Espindle D, Kopp Z, Brubaker L, Abrams P. User manual for the overactive bladder treatment satisfaction questionnaire (OAB-S). Version 3.0. May 9th 2008. 2016. \n                    https:\/\/eprovide.mapi-trust.org\/instruments\/overactive-bladder-satisfaction-questionnaire-version-3.0\n                    \n                  . Accessed 30 May 2017."},{"key":"3377_CR14","doi-asserted-by":"publisher","DOI":"10.1201\/9781420011678","volume-title":"Design and analysis of bioavailability and bioequivalence studies","author":"SC Chow","year":"2008","unstructured":"Chow SC, Liu JP. Design and analysis of bioavailability and bioequivalence studies, 3rd edn. London: Chapman and Hall\/CRC; 2008.","edition":"3"},{"key":"3377_CR15","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/1471-2490-12-26","volume":"12","author":"SM Notte","year":"2012","unstructured":"Notte SM, Marshall TS, Lee M, Hakimi Z, Odeyemi I, Chen WH, et al. Content validity and test-retest reliability of Patient Perception of Intensity of Urgency Scale (PPIUS) for overactive bladder. BMC Urol. 2012;12:26.","journal-title":"BMC Urol"},{"issue":"4","key":"3377_CR16","first-page":"196","volume":"11","author":"S Shah","year":"2009","unstructured":"Shah S, Nitti VW. Defining efficacy in the treatment of overactive bladder syndrome. Rev Urol. 2009;11(4):196\u2013202.","journal-title":"Rev Urol"},{"issue":"6","key":"3377_CR17","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1517\/14740338.2013.813016","volume":"12","author":"GM Rosa","year":"2013","unstructured":"Rosa GM, Bauckneht M, Scala C, Tafi E, Leone Roberti Maggiore U, Ferrero S, et al. Cardiovascular effects of antimuscarinic agents in overactive bladder. Expert Opin Drug Saf. 2013;12(6):815\u201327.","journal-title":"Expert Opin Drug Saf"},{"issue":"2","key":"3377_CR18","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.eururo.2015.09.007","volume":"69","author":"GM Rosa","year":"2016","unstructured":"Rosa GM, Ferrero S, Nitti VW, Wagg A, Saleem T, Chapple CR. Cardiovascular safety of beta3-adrenoceptor agonists for the treatment of patients with overactive bladder syndrome. Eur Urol. 2016;69(2):311\u201323.","journal-title":"Eur Urol"},{"issue":"7","key":"3377_CR19","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1111\/ijcp.12194","volume":"67","author":"VW Nitti","year":"2013","unstructured":"Nitti VW, Khullar V, van Kerrebroeck P, Herschorn S, Cambronero J, Angulo JC, et al. Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies. Int J Clin Pract. 2013;67(7):619\u201332.","journal-title":"Int J Clin Pract"},{"issue":"6","key":"3377_CR20","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1111\/bju.12649","volume":"113","author":"O Yamaguchi","year":"2014","unstructured":"Yamaguchi O, Marui E, Kakizaki H, Homma Y, Igawa Y, Takeda M, et al. Phase III, randomised, double-blind, placebo-controlled study of the beta3-adrenoceptor agonist mirabegron, 50 mg once daily, in Japanese patients with overactive bladder. BJU Int. 2014;113(6):951\u201360.","journal-title":"BJU Int"},{"issue":"7","key":"3377_CR21","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1002\/nau.22645","volume":"34","author":"HC Kuo","year":"2015","unstructured":"Kuo HC, Lee KS, Na Y, Sood R, Nakaji S, Kubota Y, et al. Results of a randomized, double-blind, parallel-group, placebo- and active-controlled, multicenter study of mirabegron, a beta3-adrenoceptor agonist, in patients with overactive bladder in Asia. Neurourol Urodyn. 2015;34(7):685\u201392.","journal-title":"Neurourol Urodyn"},{"issue":"6","key":"3377_CR22","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1007\/s00345-014-1244-2","volume":"32","author":"CR Chapple","year":"2014","unstructured":"Chapple CR, Nitti VW, Khullar V, Wyndaele JJ, Herschorn S, van Kerrebroeck P, et al. Onset of action of the beta3-adrenoceptor agonist, mirabegron, in phase II and III clinical trials in patients with overactive bladder. World J Urol. 2014;32(6):1565\u201372.","journal-title":"World J Urol"}],"container-title":["International Urogynecology Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00192-017-3377-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00192-017-3377-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00192-017-3377-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,29]],"date-time":"2019-08-29T10:17:12Z","timestamp":1567073832000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00192-017-3377-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,15]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["3377"],"URL":"https:\/\/doi.org\/10.1007\/s00192-017-3377-5","relation":{},"ISSN":["0937-3462","1433-3023"],"issn-type":[{"value":"0937-3462","type":"print"},{"value":"1433-3023","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,15]]},"assertion":[{"value":"11 January 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"David Staskin has received grants, speaker and consultancy fees from Astellas, speaker and consultancy fees from Allergan, Velicept, StimGuard, NewUro, and Inpellis, and has patents related to surgical devices for stress incontinence with royalties paid.Sender Herschorn has received grants, speaker and consultancy fees from Astellas, Allergan, and Ipsen, and speaker and consultancy fees from Merus and Pfizer.Jonathan Fialkov has received investigator fees from Astellas, and is managing director\/board chairman of Rational Surgical Solutions, and has received sponsorship fees from Dendreon for Rational Surgical Solutions software application.Le Mai Tu has received speaker and consultancy fees from Astellas and Pfizer.Terry Walsh and Carol Schermer are employees of Astellas.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"The Institutional Review Board (IRB) reviewed the ethical, scientific and medical appropriateness of the study before it was conducted. IRB approval of the protocol, informed consent and patient information and\/or advertising, as relevant, was obtained prior to the study commencing. This study was conducted in accordance with the ethical principles that have their origin in the Declaration of Helsinki, Good Clinical Practice, and International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use guidelines and applicable laws and regulations.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"United States: Palm Beach Research (Florida); Alaska Clinical Research Center (Alaska); Skyline Urology (Sherman Oaks - California); Skyline Urology (Torrance - California); Urology Centers of Alabama (Alabama); Accumed Research Associates (New York); Clinical Research and Consulting Center, LLC (Virginia); Iowa Clinic (Iowa); Health Research of Hampton Roads Inc. (Virginia); Advanced Clinical Research of Miami (Florida); Jackson Clinic PA (Tennessee); Pinellas Urology Inc. (Florida); Urological Associates of Southern Arizona (Arizona); Advanced Urology Centers of New York-Bethpage, Clinical Research Division (New York); Mid Atlantic Urology Associates, LLC (Maryland); Chesapeake Urology Associates PA (Maryland); Millennium Clinical Research Center (Virginia); Genesis Research Center (California); Eastern Research (Florida); Coastal Connecticut Research, LLC (Connecticut); Boston Clinical Trials Inc. (Massachusetts); Clinical Research Consulting LLC (Connecticut); Practice Research Organization, Inc. (Texas); Upstate Clinical Research Associates (New York); Suffolk Obstetrics and Gynecology (New York); North Shore LIJ Health System (New York); Institute For Female Pelvic Medicine (Pennsylvania); Nevada Access To Research and Education Society (Nevada).Canada: CHUS - Hopital Fleurimont (Quebec); Jonathan Giddens Medicine Professional Corporation (Ontario); Recherches Clinique Theradev (Quebec); The Male\/Female Health and Research Centre (Ontario); Recherche GCP Research (Quebec); Silverado Research Inc. (British Columbia); Scisco Clinical Research (Ontario); Glover Medical Clinic (British Columbia).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Institutions\/study centers"}}]}}